You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD20

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory Trial in China (Orelabrutinib, Recombinant humanized mAb MIL62 injection)

Active, not recruiting
  • B-cell Lymphoma Recurrent
  • B-cell Lymphoma Refractory
  • Orelabrutinib
  • Recombinant humanized monoclonal antibody MIL62 injection
  • Bengbu, Anhui, China
  • +9 more
Nov 11, 2022

Large B-cell Lymphoma Trial in Philadelphia (mosunetuzumab, glofitamab, obinutuzumab)

Recruiting
  • Large B-cell Lymphoma
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Jul 21, 2022

DLBCL (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)

Active, not recruiting
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

B Cell Non-Hodgkin's Lymphoma Trial in Duarte (CD19/CD20-directed CAR-T cells)

Recruiting
  • B Cell Non-Hodgkin's Lymphoma
  • CD19/CD20-directed CAR-T cells
  • Duarte, California
    City of Hope Medical Center
Aug 10, 2022

Early Stage Follicular Lymphoma WHO Grade 1/2 or 3a Trial in Heidelberg (Standard, Experimental)

Recruiting
  • Early Stage Follicular Lymphoma WHO Grade 1/2 or 3a
  • Standard
  • Experimental
  • Heidelberg, Germany
    University Hospital Heidelberg
Jul 10, 2022

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Chronic Lymphocytic Leukemia Trial in Milwaukee (CAR-20/19-T cells (1.0 x10^5

Completed
Has Results
  • Lymphoma, Non-Hodgkin
  • +3 more
  • CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)
  • +3 more
  • Milwaukee, Wisconsin
    Froedtert Hospital & Medical College of Wisconsin
Jun 26, 2022

Relapase and Refractory B-cell Non-Hodgkin's Lymphoma, Decitabine-primed Tandem CD19/CD20 CAR T Cells Trial in Beijing

Recruiting
  • Relapase and Refractory B-cell Non-Hodgkin's Lymphoma
  • Decitabine-primed Tandem CD19/CD20 CAR T Cells
  • Decitabine-primed Tandem CAR19/20 engineered T cells
  • Beijing, Beijing, China
    Biotherapeutic Department of Chinese PLA General Hospital
Mar 24, 2022

B-cell Non-Hodgkin's Lymphoma Trial in Beijing (CD19/CD20 Dual-CAR-T cells)

Suspended
  • B-cell Non-Hodgkin's Lymphoma
  • CD19/CD20 Dual-CAR-T cells
  • Beijing, Beijing, China
    Beijing Tsinghua Changgung Hospital
Jan 29, 2022

CD20 Positive Non Hodgkin Lymphoma Trial in United States (CPO107)

Recruiting
  • CD20 Positive Non Hodgkin Lymphoma
  • Los Angeles, California
  • +4 more
Aug 9, 2022

Advanced Malignancies Trial in Beijing (1A46 Drug Substance)

Not yet recruiting
  • Advanced Malignancies
  • 1A46 Drug Substance
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Aug 4, 2023

Health Status of Children Born After Assisted Reproductive

Recruiting
  • Children Born After Assisted Reproductive Technologies
  • +2 more
  • hemogram examination
  • Almaty, Kazakhstan
    Sevara ilmuratova
Oct 17, 2023

Acute Lymphocytic Leukemia Trial in Beijing, Tianjin (LCAR-AIO Cells)

Recruiting
  • Acute Lymphocytic Leukemia
  • LCAR-AIO Cells
  • Beijing, Beijing, China
  • +1 more
May 31, 2022

PTLD, CAEBV, HLH Trial in Beijing (low-dose CD20 mAb injection)

Enrolling by invitation
  • PTLD
  • +2 more
  • low-dose CD20 monoclonal antibody injection
  • Beijing, Beijing, China
    Beijing Friendship Hospital
Feb 24, 2022

Mantle Cell Lymphoma Trial in Duarte (drug, procedure, biological)

Not yet recruiting
  • Mantle Cell Lymphoma
  • Duarte, California
    City of Hope Medical Center
Sep 20, 2023

Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma Trial in Milano (intralesional rituximab, supplemental autologous

Completed
  • Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma
  • intralesional rituximab
  • supplemental autologous serum
  • Milano, Italy
    Dip. Oncoematologia - Fondazione Centro San Raffaele del Monte T
Aug 2, 2022

Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in France, Germany, United States (Odronextamab multiple dose levels)

Recruiting
  • Non-Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
  • Odronextamab multiple dose levels
  • Orange, California
  • +20 more
Dec 14, 2022

B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory Trial in Beijing, Tianjin (LCAR-AIO cells product)

Recruiting
  • B-cell Lymphoma Recurrent
  • B-cell Lymphoma Refractory
  • LCAR-AIO cells product
  • Beijing, Beijing, China
  • +1 more
Apr 1, 2022

Non-Hodgkin's Lymphoma (Disorder), Acute Lymphoid Leukemia, Disease (Disorder) Trial in Louisville, Houston (1A46 Injection)

Recruiting
  • Non-Hodgkin's Lymphoma (Disorder)
  • Acute Lymphoid Leukemia, Disease (Disorder)
  • 1A46 Injection
  • Louisville, Kentucky
  • +1 more
Aug 1, 2022

Lymphoma, B-Cell, Lymphoma, Non-hodgkins, Chronic Lymphocytic Leukemia Trial run by the NCI (Anti-cluster of differentiation 19

Terminated
Has Results
  • Lymphoma, B-Cell
  • +3 more
  • Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptors (CAR) and Anti-cluster of differentiation 20 (CD20)-CAR T cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 26, 2022

Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma Trial in Duarte

Not yet recruiting
  • Blastoid Variant Mantle Cell Lymphoma
  • +2 more
  • Biopsy
  • +8 more
  • Duarte, California
    City of Hope Medical Center
May 15, 2023

19 and 22+ B Cell Hematologic Tumors Trial in Wuhan (Autologous CD19/CD22 Chimeric Antigen Receptor T-cells)

Recruiting
  • 19 and 22+ B Cell Hematologic Tumors
  • 19 and 20+ B Cell Hematologic Tumors
  • Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells
  • Wuhan, Hubei, China
    Tongji Hospital
Jan 11, 2023

Cladribine Therapy After Anti CD20 Therapy

Active, not recruiting
  • Multiple Sclerosis
  • Cladribine Oral Tablet
  • +2 more
  • Lugano, Ticino, Switzerland
    Neurocenter of Southern Switzerland, Ospedale Regionale di Lugan
Mar 22, 2022

Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,

Completed
  • Grade 3a Follicular Lymphoma
  • +9 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 31, 2023

Diffuse Large B Cell Lymphoma Trial in Berlin (Ibrutinib and Bortezomib + R-CHOP)

Active, not recruiting
  • Diffuse Large B Cell Lymphoma
  • Ibrutinib and Bortezomib + R-CHOP
  • Berlin, Germany
    Charité - Universitätsmedizin Berlin, Hematology, Oncology and T
Aug 10, 2022

Membranous Nephropathy Trial in Bergamo, Ranica (MOR202)

Recruiting
  • Membranous Nephropathy
  • Bergamo, BG, Italy
  • +1 more
Mar 4, 2022